Skip to main content
Signal8

Jaguar Health, Inc. (JAGX) Form 10-Q — Nov 16, 2026

$JAGXForm 10-QFiled Nov 16, 2026, 6:39 AM ET0001193125-26-461940Original filing

Jaguar Health filed its Q3 2026 10-Q reporting $23.8 million in nine-month revenue, up sharply from $8.3 million a year ago, driven almost entirely by $20.8 million of license and supply revenue from the Woodward Specialty agreement covering Mytesi and Canalevia-CA1. Net loss narrowed to $9.9 million from $30.8 million. The filing contains substantial-doubt going-concern language: the company holds just $5.5 million in cash against an accumulated deficit of $409.5 million, and management concedes current resources are insufficient to fund operations for one year. Woodward alone accounts for 98% of revenue, creating extreme customer concentration.

Key figures

Revenue
23840000
Total Debt
2493000
Total Assets
32511000
Cash Position
5528000
Shares Outstanding
13345986
Q3 revenue
2343000
Q3 net loss
5830000
Going concern
Yes
Reverse splits
1-for-35 (April 30, 2026) and 1-for-15 (September 17, 2026)
Accumulated deficit
409500000
Woodward license revenue
20800000
Woodward revenue concentration pct
98

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.